Neovasc Comments on Article in Journal of the American Heart Association -- Study Shows Potential For Reducer
11:12 AM EST, 02/05/2021 (MT Newswires) -- Neovasc, Inc. (NVCN.V), up nearly 4% on last look, announced that the Journal of the American Heart Association has published an article entitled, "Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina".
The article, authored by Mina Owlia, M.D., New York University School of Medicine, explored the relationship between Canadian Cardiovascular Society (CCS) angina severity classification and all-cause mortality and healthcare utilization. The retrospective analysis of veterans in the United States utilized natural language processing to identify over 14,000 patients suffering from angina.
The study found that patients suffering from angina had worse outcomes and higher rates of healthcare utilization than patients without angina. Hospitalizations, stenting procedures and bypass graft surgeries were also more likely to occur in patients with the most severe classes of angina.
Neovasc's Reducer is not approved for commercial use in the United States, but the FDA granted Breakthrough Device designation to the Reducer in October 2018. This designation expedites the development and review of a device that demonstrates compelling potential to provide a more effective treatment or diagnosis.
"Angina is a predictor of poor outcomes for patients and as indicated in this large study, CCS classification as used in the original Reducer COSIRA study was indeed a very good measure to focus on," said Fred Colen, Chief Executive Officer of Neovasc. "CCS classifcation in this study was positively associated with all-cause mortality and healthcare utilization for cardiovascular causes."
Price: 1.85, Change: +0.07, Percent Change: +3.93